Immunology and Microbiology
Antibody Titer
5%
Atopic Dermatitis
97%
Breakthrough Infection
13%
CD20
9%
Ciclosporin
9%
Cutaneous T Cell Attracting Chemokine
6%
Cytokine
6%
Cytotoxic T-Cell
14%
Dupilumab
9%
Eczema
24%
Humoral Immunity
16%
Imiquimod
7%
Immune Response
6%
Immune-Mediated Inflammatory Diseases
34%
Immunoglobulin E
6%
Immunosuppressant
22%
Immunosuppressive Drug
9%
Inflammatory Disorder
8%
Interleukin 13
10%
Interleukin 17
5%
Monoclonal Antibody
5%
Multiple Sclerosis
6%
Omicron Coronavirus Variant
5%
Programmed Cell Death
5%
Regulatory T Cell
13%
Seroconversion
13%
Severe Acute Respiratory Syndrome Coronavirus 2
48%
Squamous Cell
11%
Staphylococcus Aureus
11%
Synovial Fluid
5%
T Cell
16%
T Cell Activation
5%
T-Helper Cell
6%
Thymus and Activation Regulated Chemokine
14%
TNF Inhibitor
10%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
15%
Atopic Dermatitis
100%
Baricitinib
7%
Biological Marker
19%
Cohort Study
6%
Disease Activity
24%
Diseases
8%
Dupilumab
19%
Eczema
10%
Immunosuppressive Agent
10%
Infection
6%
Inflammatory Disease
19%
Janus Kinase Inhibitor
5%
Monoclonal Antibody
5%
Neurodermatitis
5%
Placebo
8%
Proteinase
5%
Pruritus
19%
Randomized Controlled Trial
5%
SARS Coronavirus
18%
Thymus and Activation Regulated Chemokine
7%
Topical Corticosteroid
9%
Tralokinumab
11%
Upadacitinib
12%
Medicine and Dentistry
Adverse Event
6%
Atopic Dermatitis
49%
Biological Marker
9%
Cohort Analysis
5%
Coronary Artery
9%
COVID-19
5%
COVID-19 Vaccination
13%
Cytotoxic T-Cell
5%
Dermatology
9%
Disease Activity
8%
Diseases
7%
Eczema
10%
Imiquimod
7%
Immunosuppressant
5%
Immunosuppressive Drug
6%
Inflammatory Disorder
19%
Janus Kinase Inhibitor
5%
Macrophage
6%
Messenger RNA
9%
Neoplasm
7%
Pruritus
5%
Quality of Life
9%
Severe Acute Respiratory Syndrome Coronavirus 2
9%
Squamous Cell Carcinoma
10%
T Cell
11%
TNF Inhibitor
9%
